White House unveils nine new drug-price deals with pharma firms
The White House announced nine additional MFN-style drug-pricing deals with pharma firms (bringing total to 26) intended to lower prices for Medicaid and align U.S. prices with other wealthy nations; details are largely confidential, prompting calls from Democrats for transparency. The administration also highlights the Medicare GLP-1 Bridge Program, which has saved seniors money, and urges Congress to codify MFN pricing into permanent law.